Vaccines

GSK's investigational Ebola vaccine is in Phase I safety trials.

Johnson& Johnson is collaborating with WHO and others on clinical testing, development, production, and distribution of an Ebola vaccine.

IDT Biologika completes large-scale biologics finishing facility in Dessau, Germany.

NIH seeks new therapeutic products to bolster the protective properties of vaccines.

Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.

CALIXAR and VirPath use new manufacturing techniques to create a vaccine for the pandemic flu, influenza A (H1N1), available in 2015.

Texas A&M dedicates national pandemic influenza vaccine manufacturing facility.

FDA gives NewLink Genetics approval to proceed to Phase 1 clinical studies of Ebola vaccine.

The National Institute of Allergy and Infectious Diseases will begin the first in a series of trials for an Ebola vaccine during the week of Sept. 1.

EMA has released the second module of a new guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of a module on the quality requirements.

Pfizer announced an agreement to acquire Baxter International?s marketed vaccines for $635 million.

Redbiotec and GE Healthcare Life Sciences develop a novel manufacturing process for virus-like particles.

The regulatory filing marks the first step in the approval process toward making RTS,S available as an addition to existing tools currently recommended for malaria prevention.

Novartis facility becomes the first US site licensed by the FDA to produce cell-culture influenza vaccines.

GSK reports 5-year vaccine price freeze for countries graduating from GAVI Alliance.

New formulations and expanded vaccine production are encouraged.

FDA develops an assay that could speed the release of pandemic influenza vaccines.

Pfizer intends to submit a biologics license application for its investigational Meningococcal B vaccine candidate, Bivalent rlp2086, to FDA by mid-2014.

HHS plan makes progress in ensuring availability of safe vaccines.

EMA releases an update on its flu vaccine guidance.

A study led by Stanford University explains why men may have weaker responses to vaccines than women.

A monkey-vaccine study provides insight into HIV research.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Pfizer appoints management changes to take effect in 2014.

European Medicines Agency announces the launch of the Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE) project.

John J. Castellani, President and CEO of the Pharmaceutical Research and Manufacturers of America of the PhRMA Research & Hope awards and creating an ecosystem for promoting new vaccine development

GSK and the Gates Foundation will invest a combined $1.8 million in early stage research into vaccine thermostability.

Scientific Digital Imaging's Synbiosis Division introduces SynStats statistical analysis software.

Pfenex modifies its contract with US government for Anthrax vaccine.